ライフサイエンスコーパス: malignancy

1 ellular carcinoma (HCC, one of the deadliest malignancies).

2 nd there is no targeted therapy against this malignancy.

3 id lesions (SUV(max), 3.3-9.9) suggestive of malignancy.

4 a new predisposing medical condition, as in malignancy.

5 ogenic processes in tumors, leading to tumor malignancy.

6 resents the second most frequent hematologic malignancy.

7 be severe and debilitating and often mimics malignancy.

8 is and increased risk for developing myeloid malignancy.

9 ibutor to the development and progression of malignancy.

10 n serve as a diagnostic marker for this rare malignancy.

11 lomerular filtration rate (GFR), and reduced malignancy.

12 Metabolic reprogramming is a hallmark of malignancy.

13 tudied in relevant mouse models of cutaneous malignancy.

14 ding development of aging-associated myeloid malignancy.

15 ased therapies against this virus-associated malignancy.

16 function, and increased incidence of myeloid malignancy.

17 nd that it is not a tumor-suppressor in this malignancy.

18 r (PTC) is the most common type of endocrine malignancy.

19 and noncardiovascular disease, for example, malignancy.

20 d as a rapidly emerging risk factor for this malignancy.

21 fic genetic abnormalities that contribute to malignancy.

22 ecurrent infections, autoimmune disease, and malignancy.

23 a top predictive feature in the diagnosis of malignancy.

24 vo, offering a therapeutic strategy for this malignancy.

25 the PDE4 subfamily of phosphodiesterases in malignancy.

26 ajor factor responsible for tumor growth and malignancy.

27 al features of this remarkably heterogeneous malignancy.

28 n the tumor-associated stroma contributes to malignancy.

29 nt role for the HIF/NICI/SLC2A3 axis in this malignancy.

30 TC was defined as same-nodule histologic malignancy.

31 otential factor to suppress TMPRSS2-mediated malignancy.

32 ts (OTRs) are at increased risk of cutaneous malignancy.

33 lvage therapy, and for diffuse bleeding from malignancy.

34 irectly or engage the immune system to fight malignancy.

35 of enzalutamide to better manage this common malignancy.

36 risk of transformation from CH to a myeloid malignancy.

37 cers, including central nervous system (CNS) malignancies.

38 ssues and its tumorigenic functions in these malignancies.

39 hologies such as developmental disorders and malignancies.

40 a (PDAC) remains one of the most challenging malignancies.

41 th than are patients with non-haematological malignancies.

42 fforts and are linked to a restricted set of malignancies.

43 thereby obliterating PTEN deficiency-induced malignancies.

44 nd augmented antitumour activity in multiple malignancies.

45 pesviruses and are important in a variety of malignancies.

46 notherapy for the treatment of many advanced malignancies.

47 usion is fundamental in managing hematologic malignancies.

48 f-life care for patients with haematological malignancies.

49 (hIL-6) that is expressed in KSHV-associated malignancies.

50 ith higher anti-tumor immunity in most solid malignancies.

51 o understand its regenerative properties and malignancies.

52 cinomas (MIBCs) are aggressive genitourinary malignancies.

53 ts for immunotherapeutic approaches to treat malignancies.

54 ting PROs in future trials of haematological malignancies.

55 mplicated in the pathogenesis of hematologic malignancies.

56 ease for incident advanced liver disease and malignancies.

57 treatment of different types of hematologic malignancies.

58 n children and adolescents who develop these malignancies.

59 r targeting Wnt and Hippo signaling in human malignancies.

60 rous hematologic malignancies and epithelial malignancies.

61 -T cell therapy is effective for hematologic malignancies.

62 ponses and increased risks of infections and malignancies.

63 CCA as well as prospectively across diverse malignancies.

64 erations across a diverse group of pediatric malignancies.

65 potent new approach to treat haematological malignancies.

66 nvolved in the angiogenic process of several malignancies.

67 CAR T cells that target CD19(+) hematologic malignancies.

68 dism and a minimal risk of radiation-induced malignancies.

69 d neutropenia in patients with hematological malignancies.

70 s (LSCs) maintains this pathway activated in malignancies.

71 remains among the most lethal of solid tumor malignancies.

72 and neurodegenerative conditions and various malignancies.

73 ate efficacy in the treatment of hematologic malignancies.

74 r progression - with some success in certain malignancies.

75 utcomes for patients with advanced cutaneous malignancies.

76 nce ACT against solid tumors and hematologic malignancies.

77 RCTs) involving patients with haematological malignancies.

78 ividuals with other solid and haematological malignancies.

79 ion of a variety of solid and haematological malignancies.

80 commendations for melanoma and hematological malignancies.

81 ively evaluated in patients with hematologic malignancies.

82 his oncogenic transcription factor to manage malignancies.

83 en expanded for the treatment of intraocular malignancies.

84 s can be observed in patients with nonbreast malignancies.

85 patients with relapsed or refractory B-cell malignancies.

86 at are shared across multiple haematological malignancies.

87 d reminiscent of other memory and PC-derived malignancies.

88 man cancers and has been linked to oncogenic malignancies.

89 en shown to drive carcinogenesis in multiple malignancies.

90 initiating cell populations in diverse human malignancies.

91 3A) are frequently observed in hematological malignancies(1-3) and clonal hematopoiesis(4,5).

92 ients undergoing adrenalectomy for secondary malignancy (2002-2015) at 6 institutions.

93 rolled patients with advanced haematological malignancies (2008 WHO criteria) harbouring an IDH2 muta

94 transmitted most commonly (67%), followed by malignancies (29%), and other disease processes (6%).

95 ; (2) the patient had a known advanced-stage malignancy; (3) the patient already have confirmative di

96 ed identify a similar percentage of invasive malignancies (37.4% [72 of 191] vs 29.0% [52 of 179] at

97 ikely to have typical risk factors including malignancy (7.0% vs 29.4%; relative risk [RR], 0.2 [95%

98 Most common final diagnoses were malignancies 71 (36%), intestinal obstruction 11 (6%) an

99 The fourth patient showed no evidence of malignancy 8 years after diagnosis.

100 cant proportion of patients with hematologic malignancies admitted to hospital are admitted to ICU.

101 or UV-B-irradiated mice did not develop skin malignancies after infection.

102 ied data on patients with active or previous malignancy, aged 18 years and older, with confirmed seve

103 ed with day 30 mortality, whereas underlying malignancy, allogeneic hematopoietic stem cell transplan

104 es (n = 1596), there were 3 incident hepatic malignancies and 60 deaths, but the associations between

105 ratory study, 8 patients with advanced solid malignancies and an indication for sorafenib treatment w

106 lized treatment strategies for primary brain malignancies and brain metastases.

107 the FA pathway induces mutation, accelerates malignancies and causes the rapid attrition of blood ste

108 andscape of treatment approaches for several malignancies and continuing to increase patient survival

109 Data regarding associated hematologic malignancies and effective therapies in CANOMAD are scar

110 and is associated with numerous hematologic malignancies and epithelial malignancies.

111 apy for the treatment of both haematological malignancies and HIV.

112 h several cancer types including hematologic malignancies and lung cancers, among others.

113 in the community, had less frequently solid malignancies and more frequently high-risk SAB.

114 for 80-90% of all PIK3CA mutations in human malignancies and represent predictive biomarkers.

115 ing TNT functionality in bone marrow derived malignancies and their microenvironment.

116 enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastas

117 ny tumor types, TAMs contribute toward tumor malignancy and are therefore a therapeutic target of int

118 ed microcysts demonstrate a very low risk of malignancy and can be classified as benign.

119 allmark of pathological processes, including malignancy and chronic inflammation.

120 required to push these hyperplastic cells to malignancy and confer mutation-specific characteristics

121 ond syndrome before development of a myeloid malignancy and could have been monitored with bone marro

122 y increased risk of incident primary hepatic malignancy and death compared with men without p.C282Y o

123 hly advantageous as a potential biomarker of malignancy and early therapeutic response.

124 r, when we considered histologic findings of malignancy and follicular proliferation positive because

125 G-PET/CT can visualize both inflammation and malignancy and offers a whole-body assessment.

126 es for patients with COVID-19 without active malignancy and provide preliminary insights into the lym

127 rine crosstalk from tumor core that promotes malignancy and therapy resistance of edge cells.

128 that Nod2 protects from HFD-dependent liver malignancy and this protection is accompanied by decreas

129 rogression and survival outcomes of a future malignancy and warrant prospective investigation of APOE

130 ce of halo and overall observer suspicion of malignancy) and were correlated with the histopathologic

131 -fold, identified all potentially aggressive malignancies, and allowed apparently safe nonoperative s

132 gic exploration of CRCs across various human malignancies, and consolidate the strategy and methodolo

133 national registers for hospital admissions, malignancies, and death regarding liver, cardiovascular,

134 ilable for 143 nodules (122 HCCs, 18 non-HCC malignancies, and three benign nodules).

135 %, 93%, 89%, 21%, and 89%, respectively, for malignancy, and a specificity of 73%, 73%, 73%, 93%, and

136 athyroidectomy, neck dissections for thyroid malignancy, and adrenalectomy from 2008 to 2017.

137 of both genitourinary and non-genitourinary malignancy, and greater risks of systemic disease.

138 ure in patients with eyelid and conjunctival malignancy, and it is useful in identifying sentinel lym

139 Hematologic malignancies are a heterogeneous group of diseases with

140 lioblastoma multiforme (GBM) and other solid malignancies are heterogeneous and contain subpopulation

141 herapy (RT) for central nervous system (CNS) malignancies are often long-lasting without any clinical

142 Furthermore, hematologic malignancies arising in NrasG12D/G12D,C181S compound het

143 giocarcinoma (CCA) is the second most common malignancy arising in the liver.

144 ing the evaluation of a possible hematologic malignancy, as an incidental discovery during molecular

145 pecimens from 5,954 patients with refractory malignancies at 1,117 accrual sites were analyzed centra

146 single patient, diagnosis of a hematopoietic malignancy at a younger age than seen in the general pop

147 stem cell transplantation for hematological malignancy at St.

148 ey cancer has unique features that make this malignancy attractive for therapeutic approaches that ta

149 rticosteroids (44.4%) or a high suspicion of malignancy because of known pre-existing systemic malign

150 exhibit clinical efficacy for treating these malignancies, but also attack normal B cells leading to

151 ell therapy has shown promise in hematologic malignancies, but its application to solid tumors has be

152 GI cancer types has decreased, this group of malignancies continues to pose major challenges to publi

153 sis; previous history of VTE; thrombophilia; malignancy; critical illness; and infections.

154 us thromboembolism (VTE), such as older age, malignancy (cumulative incidence of 7.4% after a median

155 of infection, first acute rejection episode, malignancy, de novo donor specific antibody, posttranspl

156 re COVID-19 positive, of whom 117 had active malignancy, defined as those receiving cancer-directed t

157 hosis, hepatocellular carcinoma, solid organ malignancies, diabetes mellitus, cardiovascular disease,

158 Bone marrow surveillance before myeloid malignancy diagnosis was done in three (33%) of nine pat

159 an association between CH and hematopoietic malignancy, discuss features of CH that are predictive o

160 transplant in patients with a prior treated malignancy do not account for current staging, disease b

161 ates for antitumor drug design for pediatric malignancies driven by the MYC oncogene.

162 sed breast cancer, is typically an incurable malignancy due to the lack of targetable surface targets

163 ting that this risk is associated with other malignancies (e.g. renal cell carcinoma), little is know

164 a paradigm in treating certain hematological malignancies, efforts to translate this success to solid

165 D symptoms combined with warning symptoms of malignancy (eg, dysphagia, weight loss, bleeding) and th

166 Patients with hematologic malignancies endure immense physical and psychological s

167 ifaceted immune cell activation within brain malignancies entailing converging transcriptional trajec

168 uent inactivating mutations in mature B cell malignancies, especially in the MYD88(L265P), CD79B muta

169 yielded impressive results in several B cell malignancies, establishing itself as a powerful means to

170 nal impairment), and those with a history of malignancy (excluding kidney cancer).

171 ed ESKD risk, participants with a history of malignancy exhibited a substantially elevated risk for E

172 f patients with a history of a pretransplant malignancy for transplant candidacy.

173 PC is an orphan malignancy for which diagnostic workup and treatment is

174 628 women) with a cancer yield of 1.86% (810 malignancies found among 43 628 women; 95% CI: 1.73%, 1.

175 % CI: 1.73%, 1.98%) and a PPV3 of 16.6% (810 malignancies found among 4894 women).

176 -small-cell lung cancer, five gynaecological malignancy, four colorectal cancer, one melanoma, and se

177 her M-MDSC at day 14 had significantly lower malignancy-free survival.

178 lity epidemiological data for haematological malignancies from these regions are scarce.

179 Patients with hematologic malignancies had higher median viral loads (C(T) = 25.0)

180 However, to date, ICB monotherapy in such malignancies has been ineffective.

181 ven to be effective cancer therapies in many malignancies, has spawned great interest in developing b

182 Hematological malignancies have long been at the forefront of the deve

183 Multiple prior malignancies, hemophagocytic lymphohistiocytosis, congen

184 The impact of the EphA2 receptor on cancer malignancy hinges on the two different ways it can be ac

185 re successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneit

186 umors (GCTs) in men develop into hematologic malignancies; however, the clonal origins of such malign

187 ssociations between homozygosity and hepatic malignancy (HR, 2.1 [95% CI, 0.7-6.5]; P = .22) and deat

188 Survivors of childhood hematologic malignancies (HSCT N = 112 [70% allogeneic, 30% autologo

189 eminomas (PMNs) and hematologic somatic-type malignancies (HSTMs).

190 l body CT scan to detect synchronous primary malignancies in cancer patients undergoing a staging wor

191 which NSPs should be collected for the major malignancies in children.

192 sion has been related to the pathogenesis of malignancies in other types of tissues, so we investigat

193 Methods: Fifty-six patients with suspected malignancies in the thorax or abdomen underwent whole-bo

194 epresent the most common type of hematologic malignancies in the Western hemisphere.

195 vesicle (EV) analysis to identify markers of malignancy in an attempt to better stratify these lesion

196 t for Kaposi's sarcoma (KS), the most common malignancy in HIV/AIDS patients.

197 inoma (HGSOC) is the most lethal gynecologic malignancy in industrialized countries and has limited t

198 t for Kaposi's sarcoma (KS), the most common malignancy in people living with human immunodeficiency

199 emonstrates a shared mechanism with lymphoid malignancy in the formation of public rheumatoid factor

200 cancer remains the most common gynecological malignancy in the United States.

201 complications including an increased risk of malignancy (in particular, cholangiocarcinoma) and bilia

202 Definitive treatment of hepatobiliary malignancies include surgical resection, ablation, and l

203 Risk factors for malignancy included concomitant diagnosis of primary scl

204 that are increased in patients with numerous malignancies including viral-derived hepatocellular carc

205 itors in the treatment of multiple different malignancies, including AML.

206 is a leading therapeutic strategy in B-cell malignancies, including chronic lymphocytic leukemia (CL

207 signaling pathway is dysregulated in several malignancies, including gastric cancer, and is an import

208 Immunotherapy is standard of care for many malignancies, including non-small cell lung cancer, but

209 several genes associated with senescence and malignancy, including SERPINE1.

210 The main causes of recipient death were malignancy, infections, and cardiovascular disease.

211 ensor named EPA would score the clearance or malignancy involvement of dissected tumor margins by int

212 suggest that MDSC programming in response to malignancy is highly dependent on organ-specific conditi

213 he initiating genetic defect responsible for malignancy is known.

214 Complete remissions of a variety of B-cell malignancies lasting >= 3 years occurred after 51% of ev

215 Eligible patients had a haematological malignancy (leukaemia, myelodysplastic syndrome, or lymp

216 measures are important for controlling these malignancies-most importantly reducing consumption of to

217 e (DEST), we measured putative biomarkers of malignancy (MUC1, MUC2, MUC4, MUC5AC, MUC6, Das-1, STMN1

218 were NLPHL related (n = 10), whereas second malignancies (n = 20) and nonmalignant conditions possib

219 GCs are also the origin of malignancy, namely follicular lymphoma (FL), GC B cell-d

220 stic small round cell tumor (DSRCT), a fatal malignancy occurring primarily in adolescent/young adult

221 Tax(+) and Tax(+)/interferon-gamma(-/-) malignancies of the ear, tail, and foot comprised poorly

222 individuals had a diagnosis of hematological malignancies or chronic myeloproliferative disorders.

223 Patients with hematological malignancies or undergoing hematopoietic stem cell trans

224 imaging failed to identify a distant primary malignancy or metastatic disease.

225 nancy because of known pre-existing systemic malignancy or the presence of an atypical orbital mass i

226 ied for patients with a diagnosis of CD, UC, malignancy, or benign disease (diverticular disease, Clo

227 econdary HLH as a complication of infection, malignancy, or rheumatologic disease.

228 advances made in the treatment of many other malignancies over the past few decades.

229 arate, succinate and fumarate occur in human malignancies owing to somatic mutations in the isocitrat

230 ns are observed in a spectrum of hematologic malignancies, particularly pediatric leukemias with poor

231 the microbiome on the health of hematologic malignancy patients have concentrated on the transplant

232 Patients with active hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neu

233 sensitivity is challenging with lung nodule malignancy prediction.

234 val and expansion as well as contributing to malignancy progression and providing protection of malig

235 ystem (BI-RADS) category 3, with an expected malignancy rate of less than 2%.

236 Although overall malignancy rate was similar for DM-guided biopsy (27.8%

237 nancies; however, the clonal origins of such malignancies remain unknown.

238 indicates that the mechanism of KRAS-driven malignancy remains poorly understood.

239 tiple myeloma is an incurable haematological malignancy, representing over 10% of haematological canc

240 tern of occurrence of these multiple primary malignancies represents added diagnostic value.

241 velop increased infection or lymphoreticular malignancy risk.

242 ive regimens of patients with haematological malignancies selected for unrelated donor transplantatio

243 Procedure type, malignancy, sex, and age were also independently associa

244 We discuss disease mechanisms (rather than malignancy subtypes) to provide a comprehensive descript

245 ses are common, especially in more prevalent malignancies such as breast and prostate cancer.

246 velopmental disorders with increased risk of malignancy such as Noonan syndrome.

247 Desmoplastic malignancies, such as cholangiocarcinoma (CCA), have an

248 ion varied across genetic subtypes of B-cell malignancies, suggesting a link between mechanisms of CA

249 - teratoma (41%), and secondary somatic-type malignancy +/- teratoma (20%).

250 eviously demonstrated higher specificity for malignancy than (18)F-FDG PET.

251 ymphoma (T-LBL) are aggressive hematological malignancies that are currently treated with high-dose c

252 types in terms of solid versus hematological malignancies that can be best targeted with PROTAC appro

253 how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may

254 triple negative breast and ovarian cancers, malignancies that typically succumb to taxane resistance

255 e breasts have an increased lifetime risk of malignancy that has been attributed to a higher epitheli

256 uctal adenocarcinoma (PDAC) is an aggressive malignancy that invades surrounding structures and metas

257 effects such as opportunistic infections and malignancy that limit the health and longevity of transp

258 medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of Afr

259 innate immunity is highly desirable in human malignancies, the ability of 'non-trapping' PARP1 degrad

260 For higher likelihood of malignancy, the reading time was on average increased wi

261 outcomes for patients with NUP98-rearranged malignancies, therapeutic strategies have been considere

262 overs T cell recognition of HERVs in myeloid malignancies, thereby implicating HERVs as potential tar

263 When cells progress to malignancy, they must overcome a final telomere-mediated

264 developing TME-targeted therapies for brain malignancies, this comprehensive resource of the immune

265 Using 5% and 65% malignancy thresholds defining low- and high-risk catego

266 ed in a diverse set of hematologic and solid malignancies, thus ROR2 represents a candidate antigen f

267 95% CI, 2.6-2.7) in those with a solid tumor malignancy to 12.3 (95% CI, 11.3-13.2) in those who had

268 with DDD, with higher rates associated with malignancy transmission and parasitic and fungal disease

269 tive impairment in patients with hematologic malignancies treated with blood or marrow transplantatio

270 ly relevant for patients with haematological malignancies treated with chronically administered thera

271 ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly stromal and weakly immun

272 stewardship interventions in a hematological malignancy unit: monthly antibiotic cycling for febrile

273 s, capable of causing >=7 different types of malignancies, usually in immunocompromised individuals.

274 Malignancy was accompanied by worsened hypoxia inside th

275 Hematologic malignancy was associated with increased COVID-19 severi

276 85 women who returned to biennial screening, malignancy was detected at the site of original concern

277 at least 24 months and at tissue diagnosis, malignancy was not found in any of the 196 lesions (0%)

278 The most prevalent malignancies were breast (191 [21%]) and prostate (152 [

279 Overt hematologic malignancies were diagnosed in 16 patients (36%), with t

280 Associated hematologic malignancies were diagnosed in 4 of 33 patients (12%) (s

281 Haematological malignancies were previously thought to be driven solely

282 cificities of the algorithm for diagnosis of malignancy were 98% (50 of 51 masses; 95% CI: 90%, 100%)

283 the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts f

284 erated as oncogenic lesions progress towards malignancy, which we computationally predict will alter

285 le to many patients undergoing treatment for malignancy, which would also be infeasible in a radiolog

286 None of the cases had a positive history of malignancy, while 19% of them had a positive history of

287 ed bacteremia in patients with hematological malignancies who are hospitalized for cytotoxic chemothe

288 romes, present in up to 60% of patients with malignancy who are receiving active treatment and up to

289 cal carcinomas (ACC) are rare and aggressive malignancies with limited treatment options.

290 ople living with HIV who have haematological malignancies with poor prognosis.

291 ive breast cancer (TNBC)-a highly aggressive malignancy with a dismal posttreatment prognosis-implica

292 ed 3D-MCN architecture predicted lung nodule malignancy with a high accuracy of 93.12%, sensitivity o

293 cally heterogeneous, biologically aggressive malignancy with a uniformly poor prognosis.

294 rine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapies.

295 including hepatocellular carcinoma (HCC), a malignancy with no effective treatment.

296 eloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly in the elde

297 Gastrointestinal system (GIS) malignancy with pregnancy is a very rare condition and i

298 (PDAC) is one of the most devastating solid malignancies, with only 9% of patients surviving after b

299 Lung cancer is one of most common malignancies worldwide.

300 pression of viral large T antigen (TAg), and malignancy, yet little is known about the specific integ